BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 15200743)

  • 21. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.
    Yevtushenko VY; Belous AI; Yevtushenko YG; Gusinin SE; Buzik OJ; Agibalova TV
    Clin Ther; 2007 Nov; 29(11):2319-32. PubMed ID: 18158074
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rolipram in major depressive disorder: results of a double-blind comparative study with imipramine.
    Hebenstreit GF; Fellerer K; Fichte K; Fischer G; Geyer N; Meya U; Sastre-y-Hernández M; Schöny W; Schratzer M; Soukop W
    Pharmacopsychiatry; 1989 Jul; 22(4):156-60. PubMed ID: 2668980
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Selegiline transdermal system in the prevention of relapse of major depressive disorder: a 52-week, double-blind, placebo-substitution, parallel-group clinical trial.
    Amsterdam JD; Bodkin JA
    J Clin Psychopharmacol; 2006 Dec; 26(6):579-86. PubMed ID: 17110814
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A randomized, double-blind, 24-week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive disorder.
    Colonna L; Andersen HF; Reines EH
    Curr Med Res Opin; 2005 Oct; 21(10):1659-68. PubMed ID: 16238906
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of pindolol and milnacipran versus milnacipran and placebo on plasma prolactin and adrenocorticotrophic hormone in depressed subjects.
    Isaac MB; Isaac MT
    Hum Psychopharmacol; 2003 Oct; 18(7):569-74. PubMed ID: 14533141
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of imipramine, fluvoxamine and depressive mood on autonomic cardiac functioning in major depressive disorder.
    Volkers AC; Tulen JH; van den Broek WW; Bruyn JA; Passchier J; Pepplinkhuizen L
    Pharmacopsychiatry; 2004 Jan; 37(1):18-25. PubMed ID: 14750044
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Augmentation of antidepressants with perospirone for treatment-resistant major depressive disorder.
    Sato Y; Yasui-Furukori N; Nakagami T; Saito M; Kaneko S
    Prog Neuropsychopharmacol Biol Psychiatry; 2009 Apr; 33(3):416-8. PubMed ID: 19166896
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and tolerability of venlafaxine in geriatric outpatients with major depression: a double-blind, randomised 6-month comparative trial with citalopram.
    Allard P; Gram L; Timdahl K; Behnke K; Hanson M; Søgaard J
    Int J Geriatr Psychiatry; 2004 Dec; 19(12):1123-30. PubMed ID: 15526307
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antidepressant efficacy and tolerability of milnacipran, a dual serotonin and noradrenaline reuptake inhibitor: a comparison with fluvoxamine.
    Clerc G;
    Int Clin Psychopharmacol; 2001 May; 16(3):145-51. PubMed ID: 11354236
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Comparison of the effectiveness of two treatment strategies in inpatients with a depressive disorder. A double-blind study of imipramine followed by lithium addition versus fluvoxamine followed by lithium addition].
    Birkenhäger TK; van den Broek WW; Mulder PG; Bruijn JA; Moleman P
    Tijdschr Psychiatr; 2006; 48(4):271-81. PubMed ID: 16955991
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder.
    Arnold LM; Lu Y; Crofford LJ; Wohlreich M; Detke MJ; Iyengar S; Goldstein DJ
    Arthritis Rheum; 2004 Sep; 50(9):2974-84. PubMed ID: 15457467
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metyrapone as additive treatment in major depression: a double-blind and placebo-controlled trial.
    Jahn H; Schick M; Kiefer F; Kellner M; Yassouridis A; Wiedemann K
    Arch Gen Psychiatry; 2004 Dec; 61(12):1235-44. PubMed ID: 15583115
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and tolerability of oral and intramuscular S-adenosyl-L-methionine 1,4-butanedisulfonate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicenter studies.
    Delle Chiaie R; Pancheri P; Scapicchio P
    Am J Clin Nutr; 2002 Nov; 76(5):1172S-6S. PubMed ID: 12418499
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation.
    Wohlreich MM; Mallinckrodt CH; Prakash A; Watkin JG; Carter WP
    Depress Anxiety; 2007; 24(1):41-52. PubMed ID: 16845641
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fluoxetine versus trimipramine in the treatment of depression in geriatric patients.
    Wehmeier PM; Kluge M; Maras A; Riemann D; Berger M; Kohnen R; Dittmann RW; Gattaz WF
    Pharmacopsychiatry; 2005 Jan; 38(1):13-6. PubMed ID: 15706460
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Response rate obtained using milnacipran depending on the severity of depression in the treatment of major depressive patients.
    Sugawara Y; Higuchi H; Yoshida K; Takahashi H; Kamata M; Naito S; Sato K; Shimizu T
    Clin Neuropharmacol; 2006; 29(1):6-9. PubMed ID: 16518126
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.
    Hewett K; Chrzanowski W; Schmitz M; Savela A; Milanova V; Gee M; Krishen A; Millen L; Leary MO; Modell J
    J Psychopharmacol; 2009 Jul; 23(5):531-8. PubMed ID: 18635695
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of milnacipran on cognitive dysfunction with post-stroke depression: preliminary open-label study.
    Sato S; Yamakawa Y; Terashima Y; Ohta H; Asada T
    Psychiatry Clin Neurosci; 2006 Oct; 60(5):584-9. PubMed ID: 16958942
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A comparative study of the efficacy of long-term treatment with escitalopram and paroxetine in severely depressed patients.
    Boulenger JP; Huusom AK; Florea I; Baekdal T; Sarchiapone M
    Curr Med Res Opin; 2006 Jul; 22(7):1331-41. PubMed ID: 16834832
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and tolerability of reboxetine compared with citalopram: a double-blind study in patients with major depressive disorder.
    Langworth S; Bodlund O; Agren H
    J Clin Psychopharmacol; 2006 Apr; 26(2):121-7. PubMed ID: 16633139
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.